DBV Technologies S.A. (NASDAQ:DBVT) had its target price hoisted by stock analysts at Citigroup Inc. from $43.00 to $57.00 in a research report issued on Monday. The brokerage presently has a “buy” rating on the stock. Citigroup Inc.’s target price indicates a potential upside of 28.78% from the stock’s previous close.

A number of other research firms have also recently weighed in on DBVT. Leerink Swann upped their price target on DBV Technologies from $54.00 to $60.00 and gave the stock an “outperform” rating in a report on Friday, August 25th. BidaskClub raised DBV Technologies from a “hold” rating to a “buy” rating in a report on Tuesday, July 25th. Jefferies Group LLC reissued a “buy” rating on shares of DBV Technologies in a report on Thursday, August 31st. Finally, Zacks Investment Research lowered DBV Technologies from a “buy” rating to a “hold” rating in a report on Thursday, August 31st. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating and nine have issued a buy rating to the company’s stock. The stock has an average rating of “Buy” and a consensus price target of $52.00.

Shares of DBV Technologies (NASDAQ:DBVT) opened at 44.26 on Monday. The company’s market cap is $2.04 billion. The stock’s 50 day moving average is $43.58 and its 200 day moving average is $38.33. DBV Technologies has a 52-week low of $31.87 and a 52-week high of $46.33.

WARNING: This article was posted by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are viewing this article on another website, it was copied illegally and reposted in violation of U.S. & international trademark and copyright legislation. The original version of this article can be accessed at https://www.thecerbatgem.com/2017/10/04/citigroup-inc-increases-dbv-technologies-s-a-dbvt-price-target-to-57-00.html.

A number of institutional investors have recently modified their holdings of DBVT. Janus Henderson Group PLC acquired a new stake in DBV Technologies in the 2nd quarter worth about $90,724,000. Jennison Associates LLC increased its stake in DBV Technologies by 86.4% during the 2nd quarter. Jennison Associates LLC now owns 1,002,067 shares of the company’s stock worth $35,784,000 after buying an additional 464,341 shares in the last quarter. Alliancebernstein L.P. increased its stake in DBV Technologies by 21.1% during the 1st quarter. Alliancebernstein L.P. now owns 996,535 shares of the company’s stock worth $35,098,000 after buying an additional 173,798 shares in the last quarter. Morgan Stanley increased its stake in DBV Technologies by 89.9% during the 1st quarter. Morgan Stanley now owns 249,988 shares of the company’s stock worth $8,805,000 after buying an additional 118,317 shares in the last quarter. Finally, Sectoral Asset Management Inc increased its stake in DBV Technologies by 34.2% during the 2nd quarter. Sectoral Asset Management Inc now owns 179,152 shares of the company’s stock worth $6,398,000 after buying an additional 45,653 shares in the last quarter. 45.52% of the stock is currently owned by hedge funds and other institutional investors.

DBV Technologies Company Profile

DBV Technologies SA is a France-based clinical-stage biopharmaceutical company focused on changing the field of immunotherapy by developing a technology platform called Vaskin. The Company’s therapeutic approach is based on epicutaneous immunotherapy, or EPIT, its proprietary method of delivering biologically active compounds to the immune system through intact skin using Viaskin.

Analyst Recommendations for DBV Technologies (NASDAQ:DBVT)

Receive News & Stock Ratings for DBV Technologies S.A. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DBV Technologies S.A. and related stocks with our FREE daily email newsletter.